Download video

Phase II study of acalabrutinib, venetoclax, and obinutuzumab in CLL enriched for high-risk disease

494 views

VJHemOnc – Video Journal of Hematology & HemOnc

5 years ago

Phase II study of acalabrutinib, venetoclax, and obinutuzumab in CLL enriched for high-risk disease

Phase II study of acalabrutinib, venetoclax, and obinutuzumab in CLL enriched for high-risk disease

Acalabrutinib, venetoclax and obinutuzumab upfront for CLL
1:59
Acalabrutinib, venetoclax and obinutuzumab upfront for CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Phase II study of acalabrutinib, venetoclax, and obinutuzumab in CLL enriched for high-risk disease
2:12
Phase II study of acalabrutinib, venetoclax, and obinutuzumab in CLL enriched for high-risk disease
by VJHemOnc – Video Journal of Hematology \& HemOnc
Insights into the MAJIC study: acalabrutinib + venetoclax vs venetoclax + obinutuzumab in CLL
1:50
Insights into the MAJIC study: acalabrutinib + venetoclax vs venetoclax + obinutuzumab in CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
MAJIC: Venetoclax with acalabrutinib or obinutuzumab in CLL
1:09
MAJIC: Venetoclax with acalabrutinib or obinutuzumab in CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Christine Ryan, MD, Discusses Phase II Results of Acalabrutinib, Venetoclax, Obinutuzumab in CLL
4:26
Christine Ryan, MD, Discusses Phase II Results of Acalabrutinib, Venetoclax, Obinutuzumab in CLL
by Blood Cancers Today
Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-l...
2:57
Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-l...
by ecancer
Four-year follow-up from a Phase II study of obinutuzumab, ibrutinib, and venetoclax in CLL
2:43
Four-year follow-up from a Phase II study of obinutuzumab, ibrutinib, and venetoclax in CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Acalabrutinib-obinutuzumab in CLL: 3-year follow-up
1:11
Acalabrutinib-obinutuzumab in CLL: 3-year follow-up
by VJHemOnc – Video Journal of Hematology \& HemOnc
Final results of the CLL2-BAAG trial: acalabrutinib, venetoclax, and obinutuzumab triplet in R\/R CLL
1:38
Final results of the CLL2-BAAG trial: acalabrutinib, venetoclax, and obinutuzumab triplet in R\/R CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Dr. Lampson on Safety and Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab in CLL
1:15
Dr. Lampson on Safety and Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab in CLL
by OncLive
Acalabrutinib, venetoclax and obinutuzumab in previously untreated patients with CLL
5:21
Acalabrutinib, venetoclax and obinutuzumab in previously untreated patients with CLL
by ecancer
Benjamin Lampson: Acalabrutinib Combo Leads to Deep, Durable Responses in Frontline CLL
3:18
Benjamin Lampson: Acalabrutinib Combo Leads to Deep, Durable Responses in Frontline CLL
by American Society of Hematology
Novel agent combinations for CLL: ibrutinib, venetoclax, obinutuzumab and zanubrutinib
1:46
Novel agent combinations for CLL: ibrutinib, venetoclax, obinutuzumab and zanubrutinib
by VJHemOnc – Video Journal of Hematology \& HemOnc
OAsIs trial update: ibrutinib, venetoclax plus obinutuzumab in newly diagnosed MCL
1:30
OAsIs trial update: ibrutinib, venetoclax plus obinutuzumab in newly diagnosed MCL
by VJHemOnc – Video Journal of Hematology \& HemOnc
CLARITY: a Phase 2 trial using venetoclax and ibrutinib
1:00
CLARITY: a Phase 2 trial using venetoclax and ibrutinib
by VJHemOnc – Video Journal of Hematology \& HemOnc
Combined acalabrutinib treatments for CLL
1:22
Combined acalabrutinib treatments for CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Dr. Woyach on 3-Year Follow-Up of Acalabrutinib\/Obinutuzumab Combo in CLL
1:20
Dr. Woyach on 3-Year Follow-Up of Acalabrutinib\/Obinutuzumab Combo in CLL
by OncLive
Dr. Seymour on the PFS Benefit With Acalabrutinib With or Without Obinutuzumab in CLL
0:51
Dr. Seymour on the PFS Benefit With Acalabrutinib With or Without Obinutuzumab in CLL
by OncLive
5-year update of ELEVATE CLL TN
1:24
5-year update of ELEVATE CLL TN
by VJHemOnc – Video Journal of Hematology \& HemOnc
Dr. Gerson on Venetoclax\/Obinutuzumab Combination in CLL
1:02
Dr. Gerson on Venetoclax\/Obinutuzumab Combination in CLL
by OncLive